Futureproofing Pharmaceutical Supplies with ReMediES

Reconfiguring medicines end-to-end supply

Intersys is a proud partner of the Advanced Manufacturing Supply Chain Initiative (AMSCI) ReMediES project consortium. SCAIR® has been an integral part of this innovative collaboration of more than 22 companies led by GlaxoSmithKline and the University of Cambridge’s Institute for Manufacturing. ReMediES aims to remove inefficiencies in pharma supply chains by bringing together a wide range of stakeholders. Leading global contract manufacturing organisations, equipment manufacturers, regulators, knowledge transfer networks and healthcare providers are just some of the groups working together on this pharma supply chain optimisation solution.

SCAIR® along with its parent company Intersys, have been creating support tools for the development of a more integrated end-to-end pharma supply chain for the ReMediES project. The ReMediES commercial supply chain team is focussed specifically on increasing efficiency in critical stages of supply chains from equipment selection to network integration and risk management.

Key Outcomes of Supply Chain Risk Management Sub Project

Supply chain segmentation and risk characterisation

Supply chain risk exposure assessment

Compare risk profiles, identify approaches for resilient supply network model

Supply Chain Incident monitoring

Development of SCAIR to monitor Natural Disasters and Regulatory Non Compliances in the biopharma industry

Definition and ranking of pharmaceutical supply chain risk universe

Download the ReMediES Pharmaceutical Supply Chain Risk White Paper

Intersys’ Risk Director Catherine Geyman was one of three authors of the ReMediES white paper Understanding Risk in Pharmaceutical Supply Chains.

The result of a four-year-long collaboration with University of Cambridge, AstraZeneca, GSK and other industry leaders, the paper looks at different aspects of risk management in the pharmaceutical supply chain.

The many areas covered included a ‘deep dive’ on the triggers for drug shortages and a risk-benefit analysis of clinical just-in-time manufacture.

The paper features three distinct methods to help our understanding of drug shortages. These are:

  • real-world analysis, to help better predict disruptions and supply shortages
  • expert-driven risk prioritisation, to unravel complex interdependencies between potential causes of supply failure
  • simulation-based assessment of new manufacturing technologies, to mitigate disruption and reduce inventory.

Catherine Geyman was involved in all areas of the project and led the disruption prediction analysis, using analytics that are integral to SCAIR®’s Regulatory Incident Monitor.

Work on this paper reflects SCAIR®’s long-standing investigation into current issues related to drug shortages – and possible solutions.

On our blog, we have examined the pharma supply chain reliance on India and China in the wake of COVID-19, the real reasons for UK drug shortages, and much more.

You can download Understanding Risk in Pharmaceutical Supply Chains here.